HealthLinx [ASX: HTX] has been granted a US patent related to the company's vascular permeability program.
Licensed from the University of Virginia, the patent is related to the inhibition of the p21 activated kinase pathway as a treatment for disorders caused by aberrant vascular permeability.
It has widespread potential applications, including ischemia, stroke or burns.
The patent also forms part of the drug candidate CR014, a potential treatment for acute respiratory distress syndrome (ARDS) that the company is developing with the Canadian-based InSymbiosis.
No effective therapeutic treatments are available for the disease, which has a morbidity rate as high as 40 percent.
HealthLinx and InSymbiosis are preparing to embark on a preclinical development program for CR014.
Fujitsu Introduces First Netbook Series – Fujitsu M1010, the Comprehensive Solution for Work and Play. 2008-12-15 16:30:00+11
Kingston Technology Boosts DataTraveler 150 Capacity to 64GB 2008-12-09 15:30:00+11
IDC Says Asia/Pacific Excluding Japan IT Market Will Remain The Bright Spot... 2008-12-04 15:04:00+11
AOC Launches 18.5” Widescreen Green 16:9 LCD Monitor in Australia and New Zealand 2008-12-03 15:30:00+11
NComputing Appoints Country Manager for Australia, New Zealand, and South Pacific Islands 2008-12-03 00:43:00+11
